La Jolla Pharmaceutical (LJPC +9.5%) announces preliminary GIAPREZA (angiotensin II) net sales for the three and twelve months ended December 31, 2019.
Q4 GIAPREZA net sales were $7.2M, up 71% Y/Y. Hospital demand for vials of GIAPREZA grew 74%.
For FY 2019, GIAPREZA net sales were $23.1M, +129% Y/Y.
Net cash used in operating activities for Q4 2019 was ~$17M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.